Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study

At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to ritonavir-boosted lopinavir in achieving virologic suppression in adults with HIV-1 who failed first-line therapy. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Underwood, Mark, Horton, Joe, Nangle, Keith, Hopking, Judy, Smith, Kimberly, Aboud, Michael, Wynne, Brian, Sievers, Jörg, Stewart, Eugene L., Wang, Ruolan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765460/
https://www.ncbi.nlm.nih.gov/pubmed/34694877
http://dx.doi.org/10.1128/AAC.01643-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765460/
https://www.ncbi.nlm.nih.gov/pubmed/34694877
http://dx.doi.org/10.1128/AAC.01643-21

Ejemplares similares